AlbertsD.S., LiuP.Y., HanniganE.V.: Phase III study of intraperitoneal (IP) cisplatin (CDDP) / intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer: a SWOG - GOG - ECOG Intergroup study.Proc. Am. Soc. Clin. Oncol., 1995.
2.
AllenD.G., HeintzA.P.M., TouwF.W.M.M.: A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary.Eur. J. Gynecol. Oncol.,16: 349, 1995.
3.
ArmstrongD., RowinskyE., DonehowerR.: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer.Proc. Ann. Meet. Am. Soc. Clin. Oncol.,14: A769, 1995.
4.
BastR.C.Jr.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N. Engl. J. Med.,309: 883–887, 1983.
5.
BeralV., FraserP., ChilversC.: Does pregnancy protect against ovarian cancer?Lancet,1: 1083–1087, 1978.
6.
BerchukA., KohlerM.F., MarksJ.R., WisemanR., BoydJ., BastR.C.: The P53 tumor suppressor gene frequently is altered in gynecologic cancers.Am. J. Obstet. Gynecol., 170; 246, 1994.
7.
Bokkel HiuninkW., GoreM., BolisG.: A phase II trial of topotecan for the treatment of relapsed advanced ovarian carcinoma.Prog. Proceed. Am. Soc. Clin. Oncol.,15: A, 1996.
8.
BolisG., FavalliG., DaneseS.: Weekly cisplatin given for two months versus cisplatin plus cyclophosphamide given for five months after cytoriductive surgery for advanced ovarian cancer.J. Clin. Oncol., 15,5: 1938–44, 1997.
9.
BolisG., MalstromH., MangioniJ.: Efficacy of Topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial.Ann. Oncol.7(Suppl. 5): A321. 1996.
10.
BorsellinoN., BellgrundA., BonavidaB.: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxic of human prostate carcinoma cell lines.Cancer Res.,55: 4633, 1995.
11.
BoskmanM.A., McGuireW.P., KilpatrikD.: Carboplatin plus paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.J. Clin. Oncol.,14: 1895–1902, 1996.
12.
BrodersA.C.: Carcinoma: grading and practical application.Archives of Pathology,2: 376–381, 1926.
13.
BrownR., ClugstonC., BurnsP.: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell-lines.Int. J. Cancer,55: 678, 1993.
14.
BruzzoneM.: Prognostic factors affecting long-term survival of advanced ovarian cancer (AOC) patients (PTS): univariate and multivariate analysis at 12 years follow-up.Proc. An. Soc. Clin. Oncol.,14: 286, 1994.
15.
BurgerR.A., BurmanS., WhitheR.: Phase II trial of navelbine in advanced epithelial ovarian cancer.Proc. Am. Soc. Clin. Oncol.,15A779, 286, 1996.
16.
Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Development:The reduction in risk of ovarian cancer associated with oral contraceptive use.N. Engl. J. Med.,316: 650–655, 1987.
17.
CarmichaelJ.A., ShelleyW.E., BrownL.B.: A predictive index of cure versus no cure in advanced ovarian cancer patients — replacement of second-look laparotomy as a diagnostic test.Gynecol. Oncol.,27: 268, 1987.
18.
ConteP.F., BruzzoneM., CarinoF.: High dose versus low dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord Ovest.J. Clin. Oncol.,14: 351, 1996.
19.
ConteP.F., BruzzoneM., ChiaraS.: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide in advanced ovarian cancer.J. Clin. Oncol.,4: 965, 1986.
20.
CramerD.W., HutchinsonJ.E., WelchW.R., ScullyR.E., KnappR.C.: Factors affecting the association of oral contraceptives and ovarian cancer.N. Engl. J. Med.,307: 1047–1051, 1982.
21.
CreemersG.J., BolisG., GoreM.: Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of a large European phase II study.J. Clin. Oncol.,14: 3056–3061, 1996.
22.
DabhalkerM., VionnatJ., Bostik-BrutonF.: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemoterapy.J. Clin. Invest.,94: 703, 1994.
23.
Del BinoG., LassotaP., DarzynkiewiczZ.: The S-phase cytotoxicity of camptothecin: Exp.Cell Res.,193: 27–35, 1991.
24.
Di XiaC.: Evaluation of CA-125 levels in differentiating malignant form tumors in patient with pelvic masses.Obstet. Gynecol.,72: 23–27, 1988.
25.
DonnaA., CrosignaniP., RobuttiF.: Triazine herbicides and ovarian epithelial neoplasms.Scand. J. Work Environ. Health,15: 47, 1989.
26.
EinhormN., SjovellK., KnappR.C.: Prospective evaluation of serum CA-125 levels for early detection of ovarian cancer.Obstet. Gynecol.,80: 14, 1992.
27.
EinhornN.: Preoperative evaluation of serum CA-125 levels in patients with primary epithelial ovarian cancer.Obstet. Gynecol.,67: 414–416, 1986.
28.
FayersP.M.: The prognostic value of serum CA-125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynecological Cancer.Int. J. Gynecol. Cancer,3: 285–291, 1993.
29.
FrielanderM., De GramontA., MillwardM.J.: Activity of Gemcitabine in stage 3 of 4 ovarian cancer: patients previously treated with cisplatin (CP) containing regimens.E.J.C.,33(suppl. 8): 5120, 1997.
30.
GallionH.H., PowellD.E., MorrowJ.K.: Molecular genetic changes in human epithelial ovarian malignancies.Gynecol. Oncol.,47: 137, 1992.
31.
GershensonD.H., KavanaghJ.J., CopelandL.J.: Retreatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.Obstet. and Gynecol.,73(5, pt 1): 798–802, 1989.
32.
GordonA., BookmanM., MalmstromH.: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial.Proc. Ann. Meet. Soc. Clin. Oncol.,15: A763, 1996.
33.
GreemensG.J., BolisG., GoreM.: Topotecan, an active drug in a second line treatment of epithelial ovarian cancer: results of a large European phase II study.J. Clin. Oncol.,14: 3056–3061, 1996.
34.
GriffithsC.T.: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.NCI Monogr.,42: 101, 1975.
35.
HartgeP., SchiffmanM.H., HooverR., Mc GowanL., LesherL., NorrisH.J.: A case-controlled study of epithelial ovarian cancer.Am. J. Obstet. Gynecol.,161: 10–16, 1989.
36.
HawkinsR.E., RobertsK., Wiltshaw: The prognostic significance of the half-life of serum CA-125 in patients responding to chemoterapy for epithelial ovarian carcinoma.Br. J. Obstet. Gynecol.,96(12): 1395–1399, 1989.
37.
HochsterH., SpeyerJ., WadlerS.: Phase II study of topotecan (TPT) 21- day infusion in platinum treated ovarian cancer: a highly active regimen (A NYGOG Study).Proc. Ann. Meet. Am. Soc. Clin. Oncol.,15: A775, 1996.
38.
Hong Kong Ovarian Carcinoma Study Group:A randomized study of high dose versus low dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer.Chemotherapy,35: 221, 1989.
39.
HooverR., GrayL.A., FraumeniJ.F.: Stilbestrol and the risk of ovarian cancer.Lancet,2: 1083–1086, 1977.
40.
HoskinsP.J., SwenertonK.D.: Oral etoposide is active against platinum resistant epithelial ovarian cancer.J. Clin. Oncol.,12: 60, 1994.
41.
HoskinsW.J., BundyB.N., ThigpenJ.T.: The influence of cytoreductive surgery on recurrence - free interval and survival in small volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study.Ginecol. Oncol.,47: 159, 1992.
42.
HoskinsW.J., MgGuireW.P., BradyM.F.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian cancer: Am.J. Obstet. Gynecol.,170: 974, 1994.
43.
HoskinsW.J.: Early epithelial ovarian carcinoma: principles of primary therapy: Gynecol.Oncol.,55: S91, 1994.
44.
HunterR.W., AlexanderN.D.E., SoutterW.P.: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am.J. Obstet. Gynecol.,166: 504, 1992.
45.
IskralL., CaminoF., FudaG.: CA-125 sierico: significato prognostico nel ca ovarico avanzato. Il Congresso Nazionale GOND: Controversie nel trattamento del carcinoma ovarico – Tirrenia (PI) 14-15 ottobre 1994; Abst.4 in: Trends in experimental and clinical medicine forum4(suppl. 4) 1994.
46.
JacobsI., BastR.C.Jr.: The CA-125 tumor associated antigen: A review of the literature.Hum. Reprod., 4: 1, 1989.
47.
JolyD.J., LilienfeldA.M., DiamondE.L., BrossI.D.: An epidemiologic study of the relationship of reproductive experience to cancer of the ovary.Am. J. Epidemiol.,99: 190–209, 1974.
48.
KavanaghJ.J., TresukosalD., EdwardsC.: Carboplatin reinduction after taxanes in patients with platinum-refractory epithelial ovarian cancer.T. Clin. Oncol.,13: 1584, 1995.
49.
KayeS.B., LewisC.R., PaulJ.: Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.Cancer,340: 329, 1992.
50.
KerlikowskeK., BrownJ.S., GradyD.J.: Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet.Gynecol.,80: 700, 1992.
51.
LavinP.T.: CA-125 for the monitoring of ovarian carcinoma during primary therapy.Obstet. Gynecol.,69: 223–227, 1987.
52.
LingemanC.H.: Etiology of cancer of the human ovary: A review.J.N.C.I,53: 1603–1618, 1974.
53.
LongoD.L., YoungR.C.: Cosmetic talc and ovarian carcinoma.Lancet,2: 349–351, 1979.
54.
LuesleyD., BlackledgeG., KellyK.: Failure of second look laparatomy to influence survival in epithelial ovarian cancer.Lancet,10: 599–603, 1988.
55.
MalkasianG.D.Jr.: Preoperative evaluation of serum CA-125 in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant disease.Am. J. Obstet. Gynecol.,159: 341–346, 1988.
56.
MangioniC., BolisG., PecorelliS.: Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.J. Natl. Cancer Inst.,81(19): 1464–1471, 1989.
57.
Mc GuireW., HoskinsW.J., BradyM.F.: Assessment of dose intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.J. Clin. Oncol.,13: 1589, 1995.
58.
Mc GuireW.P., HoskinsW.J., BradyH.F.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage II ovarian cancer.N. Engl. J. Med.,334: 1 prot. III, 1996.
59.
MerkelD.E., McGuireW.L.: Ploidy proliferative activity and prognosis - DNA flow cytometry of solid tumours.Cancer,65(5): 1194–1205, 1990.
60.
MikiY., SwensenJ., Shattuck-EidensP.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA-1.Science, 266, 1994.
61.
MorrisE.J., GellerH.M.: Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-1: evidence for cell cycle-independent toxicity.J. Cell Biol.,134: 757–770, 1996.
62.
MuggiaF.M., BralyP.S., BradyM.F.: Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study II # 132.Proc. Am. Soc. Clin. Oncol.,16(Ab 1257): 352, 1997.
63.
NeijtJ.P., ten Bokkel HuininkW.W., Van der BurgM.E.L.: Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.Radioth. and Oncol.,2: 19–29, 1984.
64.
NeijtJ.P., ten Bokkel HuininkW.W., Van der BurgM.E.L.: Randomized trial comparing two combination chemotherapy regimens (Heya - CAF vs CHAP-5) in advanced ovarian carcinoma.The Lancet,2: 594–600, 1984.
65.
OmuraG., BlessingJ.A., EhrilichC.E.: A randomized trial of cyclophosphamide and doxorubicin or without cisplatin in advanced ovarian carcinoma.Cancer,56: 1725, 1987.
66.
OmuraG.A., BradyM.F., DelmoreJ.E.: A randomized trial of paclitaxel at 2 dose levels and filgrastim (G-CSF) at 2 doses in platinum pretreated epithelial ovarian cancer: A Gynecologic Oncology Group, SWOG, WCCTG and ECOG study.Proc. Am. Soc. Clin. Oncol.,15: 280 A 755, 1996.
67.
OmuraG.A., BundyB.N., BerekJ.S., CurryS., Del GadoG., MortelR.: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a gynecologic oncology group study.J. Clin. Oncol.,7: 457, 1989.
68.
Ovarian Cancer Meta-analysis Project:Cyclophosphamide, Doxorubicin and Cisplatin chemotherapy in ovarian carcinoma: a meta-analysis.J. Clin. Oncol.,9: 1668–74, 1991.
69.
OzolsR. F.: Carcinoma dell'ovaio: modalità di terapia combinata e chemioterapia. In: Current therapy in ematologia e oncologia.F. Folini editore, 1995.
70.
ParkerS.L., TongT., BaldenS.: Cancer statistics, 1997. Ca Cancer J.Clin.,47: 5–27, 1997.
71.
PerezR.P., GodwinA.K., HamiltonT.C.: Ovarian cancer biology.Sem. Oncol.,18: 186, 1991.
72.
PettersonF., Ed: Annual report on the results of treatment in gynecological cancer.Int. J. Gynecol. Obstet., 21 (Suppl 36): 1–315, 1991.
73.
PiverM.S., BakerT.R., PiedmonteM., SandeckiA.M.: Epidemiology and etiology of ovarian cancer.Semin. Oncol.,18: 177–185, 1991.
74.
Rieslag, MillerB.A., HankeyB.F.: SEER Cancer Statistical Review, 1973-1991, Tables and Graphs; NIH Pub. No. 94-270, Bethesda MD: National Cancer Institute, p. 17.
75.
RoseP.G., BlessingT.A., MayerA.R.: Prolonged oral etoposide as second line therapy for platinum resistant (PLATR) and platinum sensitive (PLATS) ovarian carcinoma: A Gynecologic Oncology Group Study.Proc. Am. Soc. Clin. Oncol., 15 Ab762: 282, 1996.
76.
RowinskyE.K., GrochowL.B., HendricksC.B.: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.J. of Clin. Oncol.,10: 647–656, 1992.
77.
RubinS.C., FinstadC.L., WongG.Y.: Prognostic significance of HER-2/NEU expression in advanced epithelial cancer: a multivariate analysis.Am. J. Obstet. Gynecol.,168: 162, 1993.
78.
SchinkJ.C., HarrisL.S., GrosenE.R.: Hexamethylmelamine is an effective salvage chemotherapy after paclitaxel in women with recurrent platinum resistant ovarian cancer. Proc. Am. So.c Clin.Oncol.,14: 275, 1995.
79.
SchultzD.C., VanderveerR.L., BuetowK.: Characteristics of chromosome 9 in human ovarian neoplasia identify frequent genetic inbalance on 9q and rare alterations in 9p including CDKN2.Cancer Res.,55: 2150, 1995.
80.
SchwarzP.E.: Surgical management of ovarian cancer.Arch. Surg.,116: 99, 1981.
81.
Shattuck-EidensD., McClureM., SimardJ.: A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening.JAMA,273: 535, 1995.
82.
ShpallE., SlemmerS., BearmanS.: High dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In: Cancer of the ovary,MarkmanM., HoskinsW.J., eds., p. 327, Raven Press, New York, 1993.
83.
SlichenmyerW.J., RowinskyE.K., DonehowerR.L.: Recurrent status of camptothecine analogues as antitumor agents.J. Nalt. Cancer Inst. it.,1993; 83: 271–291.
84.
Stewart L.A., for the Advanced Ovarian Cancer trialists Group (AOCTG):Chemotherapy in advanced ovarian cancer: an overview of randomized trials.Br. Med. J.,303: 884, 1991.
85.
TakahashiH., BehbaktK., Mc GovernP.E.: Mutation analysis of the BRCA1 gene in ovarian cancers.Cancer Res.,55: 2998, 1995.
86.
TaylorA.E., WiltshawE., GoreM.R.: Long term follow-up of the first randomized study of cisplatin using carboplatin for advanced epithelial ovarian cancer.J. Clin. Oncol.,12: 2066, 1994.
87.
ten Bokkel HiuninkW., GoreM., CarmichaelJ.: Topotecan vs paclitaxel for the treatment of recurrent epithelial ovarian cancer.J. Clin. Oncol., 15/6: 2183–93, 1997.
88.
ThigpenJ.T., BlessingJ.A., BallM.: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study.J. Clin. Oncol.,12: 1748, 1994.
89.
ThigpenJ.T., VanceR.B., KahnsurT.: Second-line chemotherapy for recurrent carcinoma of the ovary.Cancer,71: 559, 1993.
90.
TorrecillasaL., CervantesG., ErazoA.: Ifosfamide and Hexamethilmelamine phase II trial rescue treatment for ovarian cancer refractory to cisplatin.Proc. Am. Soc. Clin. Oncol.,16(abst 1352), 380a, 1997.
91.
TrimbleE.L., AdamsJ.D., VenaD.: Paclitaxel for platinum refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.J. Clin. Oncol.,11: 2405–2410, 1993.
92.
Van der BurgM.E.L.: Ovarian cancer: the prognostic value of the serum half-life CA-125 during induction chemoterapy.Gynecol. Oncol.,30: 307–312, 1988.
93.
Van der ZeefA.G.J., HollemaH., SuurmeijerA.J.H.: Value of P-glycoprotein, gluthatione S-transferase pi, C-erb B-2 and P53 as prognostic factors in ovarian carcinoma.J. Clin. Oncol.,13: 70, 1995.
94.
Van WarmerdamL.J., VerweijI.J., SchellensJ.H.: Pharmacokinetics and pharmacodinamics of topotecan administered daily for 5 days every 3 weeks.Cancer Chemother. Pharmacol.,35/237, 1995.
95.
VergoteI., HimmelmannA., FrankendalB., ScheistroenM., VlachosK.V., TropeC.: Hexamethylmelamine as second-line therapy in platinum-resistant ovarian cancer.Gynecol. Oncol.,49: 282, 1992.
96.
WeisenbergerD., ScheerU., BenevonteR.: The DNA topoisomerase I inhibitor camptothecin blocks postmitotic reformation of nucleoli in mammalian cells.Eur. J. Cells Biol., 61: 189–192, 1993
97.
WoolasR.P., XuF.J., HacobI.J.: Evaluation of multiple serum marker in patients with stage I ovarian cancer.J. Natl. Cancer Inst.,85: 1748, 1993.
98.
World Health Organization.The World Health Organization collaborative study of neoplasia and steroid contraceptives: Epithelial ovarian cancer and combined oral contraceptives.Int. J. Epidemiol.,18: 538–545, 1989.
99.
YaoK.S., GodwinA.K., JohnsonS.W., OzolsR.F., O-DwyerP.J., HamiltonT.C.: Evidence for altered regulation of gamma-glutamylcisteine synthetase gene expression among cisplatinsensitive and cisplatin-resistant human ovarian cancer cell lines.Cancer Res.,55: 4367, 1995.
100.
YoungR.C., WaltonL.A., EllenbergS.S.: Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials.N. Engl. J. Med.,322: 1021, 1990.
101.
ZijlstraJ.G., DejongS., De VriesE.G.E.: Topoisomerase: new targets in cancer chemotherapy.Med. Oncol. Tumor. Pharmacother.,7: 11–18, 1990.
